Outcomes
NSCLC, toxicity
ADVERSE EVENTS, SOLID TUMORS, NSCLC
The primary objective was to determine the maximum tolerated dose (MTD) of atezolizumab when delivered with SABR in early-stage, medically inoperable NSCLC. MTD was defined as the highest dose at which no more than one of six patients developed a DLT or dose Level 3 if the MTD was not reached. Secondary objectives included the safety profile of the experimental regimen using common toxicity criteria for adverse events (CTCAE) version 4 and preliminary efficacy data by objective response rate (ORR) and PFS by response evaluation in solid tumors (RECIST) version 1.1